Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Menopause, Depression, Anxiety, Sleep, M...
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates the impact of conjugated estrogens/ bazedoxifene (CE/ BZA) on the mood (depression and anxiety) in peri- and early menopausal women.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Duavive 0.45Mg-20Mg Tablet — Duavee, marketed as Duavive in Canada.

Primary Outcomes

  • Depressive symptoms (At 4 weeks weeks after beginning study)
  • Depressive symptoms (At 8 weeks after beginning study)
  • Depressive symptoms (At 12 weeks after beginning study)
  • Depressive symptoms (At 16 weeks after beginning study)
  • Depressive symptoms (At 4 weeks after beginning study)
  • Depressive symptoms (At 8 weeks after beginning study)
  • Depressive symptoms (At 12 weeks after beginning study)
  • Depressive symptoms (At 16 weeks after beginning study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-07-03
Completion: 2025-12
Eligibility
Age: 45 Years – 60 Years
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: St. Joseph's Healthcare Hamilton
Collaborators: McMaster University, Pfizer
Principal Investigators:
  • Alison Shea, MD (PRINCIPAL_INVESTIGATOR) - St. Joseph's Healthcare, McMaster University
Contact Information
Study Contact:
Alison Shea, MD
905-521-2100
ashea@stjosham.on.ca
Leticia Hernandez Galan, PhD
2897001324
lgalan@stjosham.on.ca
Leticia Hernandez Galan, PhD
2897001324
lgalan@stjosham.on.ca
St Joseph's Healthcare
Interventions
  • Drug: Duavive 0.45Mg-20Mg Tablet — Duavee, marketed as Duavive in Canada.
Study Locations (1 sites)
St Joseph's Healthcare, Hamilton, Ontario L8P 3B7 Canada
Eligibility Criteria
Inclusion Criteria: * Females between 45-60 years of age * Able to communicate in English * In perimenopause as defined by World Health Organization (WHO) Stages of Reproductive Aging Workshop (STRAW) criteria, OR in early menopause (within 10 years of final menstrual period) * Suffering from Depressive symptoms (10+ on CES-D-10) AND/OR anxiety symptoms (10+ on GAD-7) Exclusion Criteria: * Personal history of breast/ ovarian/ endometrial cancer/ endometrial hyperplasia. * Abnormal uterine bleeding that has not been adequately investigated. * Active or past venous or arterial thromboembolic disease (deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, coronary heart disease). * Active liver disease. * Known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders. * Known or suspected pregnancy, women who may become pregnant, and nursing mothers * Partial or complete loss of vision due to ophthalmic vascular disease. * Uncontrolled hypertension (Systolic blood pressure \>160mm Hg and/ or diastolic blood pressure \>95 mm Hg) * Endocrine disease (other than thyroid disease) that may adversely affect mood (i.e., Cushing's disease, Addison's disease). For women with abnormal TSH, it will be corrected in advance of trial initiation. * Active serious suicidal ideation with intent. * Symptoms of active psychosis. * Daily use of antidepressive medication. * Use of other psychoactive or centrally acting medications within 2 weeks before study screening. * Known hypersensitivity to either CE or BZA.
Conditions Supine Hypertension, Autonomic Failure
Phase NA
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Many persons with autonomic failure often have high blood pressure when lying down (supine hypertension). This study is exploring the impact of decreased venous return to the heart (achieved by raising the head of the bed) to lessen supine blood pressure. If decreased venous return to the heart is effective at lowering supine blood pressure, these approaches may be utilized to treat supine hypertension non-pharmacologically. Raising the head of the bed decreases the amount of blood returning to the heart due to the effects of gravity. In this case, the decreased blood return to the heart may decrease blood pressure.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Tilt — Tilt of the whole bed so that the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
  • Other: Elevated trunk — Elevation of the trunk through raising just the head of the bed until the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
  • Other: Tilt - In home — Tilt of the whole bed so that the head is elevated by 8 inches overnight.
  • Other: Elevated Trunk - In home — Elevation of the trunk through raising the head 8 inches on a wedge pillow overnight.

Primary Outcomes

  • Systolic Blood Pressure (10 PM to 8 AM)
  • Systolic Blood Pressure (10 PM to 8 AM or acute session (1 hour at each elevation of the head))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-08-21
Completion: 2026-12-31
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Principal Investigators:
  • Italo Biaggioni, MD (PRINCIPAL_INVESTIGATOR) - Vanderbilt University Medical Center
Contact Information
Study Contact:
Bonnie K Black, RN
615-343-6862
bonnie.black@vumc.org
Luis E. Okamoto, MD
(615) 936-6119
luis.e.okamoto@vumc.org
Emily C Smith, RN BSN MPH
Vanderbilt University Medical Center
Interventions
  • Other: Tilt — Tilt of the whole bed so that the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
  • Other: Elevated trunk — Elevation of the trunk through raising just the head of the bed until the head is elevated by 9 and/or 12 inches in an acute trial or overnight.
  • Other: Tilt - In home — Tilt of the whole bed so that the head is elevated by 8 inches overnight.
  • Other: Elevated Trunk - In home — Elevation of the trunk through raising the head 8 inches on a wedge pillow overnight.
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Patients with autonomic failure and with supine hypertension from all races * Males and females, between 18 to 85 years Exclusion Criteria: * All medical students * Pregnant women * High-risk patients (for example: heart failure, symptomatic coronary artery disease, liver impairment, history of stroke or myocardial infarction) * History of serious allergies or asthma.
Conditions Aging, Blood Pressure, Endothelial Dysfu...
Phase NA
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

High blood pressure (BP) is the major modifiable risk factor for cardiovascular diseases (CVD) and related health conditions, particularly among postmenopausal (PM) women. In adults age ≥50 years this risk is primarily driven by above-normal systolic BP (SBP ≥120 mmHg), as diastolic BP plateaus, then decreases in older adulthood. Although SBP is lower in premenopausal women vs. age-matched men, SBP reaches, then surpasses men after age 60. As such, \>75% of PM women in the U.S. have above-normal SBP, which, in turn, is responsible for a 2-fold increase in risk of hypertension and corresponding increases in risk of CVD, chronic kidney disease and many other disorders. A key process linking high SBP to CVD and related conditions is vascular endothelial dysfunction, mediated by excessive reactive oxygen species (ROS)-induced oxidative stress and reductions in nitric oxide (NO) bioavailability. As the number of PM women is rapidly growing, further increases in SBP-related CV disorders are projected without effective intervention. * Aerobic exercise (AE) is a first-line, standard-of-care therapy for lowering BP. In PM women with baseline SBP ≥120 mmHg, AE reduces casual (resting) SBP by \~3 mmHg (back to baseline ≤4 weeks post-training), whereas 24-hour SBP is typically unchanged. However, only 25-30% of PM women meet guidelines for 150 min/week of moderate-intensity AE, citing the extensive time requirement, facility access and travel disruptions as major barriers. Another, far less recognized, limitation is that AE training consistently improves endothelial function in midlife/older men, but not in estrogen-deficient PM (PMe-) women, i.e., in \>95% of the 60+million PM women in the U.S. Thus, establishing new lifestyle therapies that induce and sustain reductions in SBP and increases in endothelial function in PMe- women with above-normal SBP is an important public health goal. * High-resistance inspiratory muscle strength training (IMST) is a time-efficient (5 minutes per session) lifestyle intervention consisting of 30 inspiratory maneuvers performed against a high resistance. Preliminary data suggest 6-weeks of IMST performed 6 days/week reduces SBP by 9 mmHg in adults with above-normal SBP (i.e., greater than 120 mmHg) at baseline. Importantly, this reduction in SBP is equal to or greater than the reduction in blood pressure typically achieved with time- and effort-intensive healthy lifestyle strategies like conventional aerobic exercise. In addition, IMST improved endothelial function in the PMe- women in a small pilot study. * To translate these promising preliminary results towards clinical practice, this randomized clinical trial is being conducted to directly compare the efficacy of a longer, clinically relevant treatment duration of IMST (3 months) against home-based, moderate-intensity (standard-of-care) AE in PMe-women. The primary outcome will be the change in casual SBP (IMST vs. AE). Changes in 24-hour SBP and endothelial function…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Other: High-resistance inspiratory muscle strength training — Participants will perform inspiratory muscle strength training.
  • Other: Aerobic exercise — Participants will perform brisk walking.

Primary Outcomes

  • Change from baseline in casual systolic and diastolic blood pressure at 3 months (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-19
Completion: 2027-02-28
Eligibility
Age: 50 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Boulder
Principal Investigators:
  • Douglas R Seals, PhD (PRINCIPAL_INVESTIGATOR) - University of Colorado, Boulder
Contact Information
Study Contact:
Daniel H Craighead, PhD
303-492-3010
imststudy@colorado.edu
Narissa P McCarty, MS
303-492-2485
imststudy@colorado.edu
Melanie Zigler, MS
303-492-2485
melanie.connell@colorado.edu
Integrative Physiology of Aging Laboratory
Interventions
  • Other: High-resistance inspiratory muscle strength training — Participants will perform inspiratory muscle strength training.
  • Other: Aerobic exercise — Participants will perform brisk walking.
Study Locations (1 sites)
Integrative Physiology of Aging Laboratory, Boulder, Colorado 80309 United States
Eligibility Criteria
Inclusion Criteria: * Postmenopausal women (\>12 months of amenorrhea) * Estrogen deficient (no hormone therapies within the previous 12 months) * Age 50 years and older * Ability to provide informed consent * Willing to accept random assignment to condition * Resting systolic blood pressure of 120 mmHg or greater * Body mass index \<40 kg/m2 * Weight stable in the prior 3 months (\<2 kg weight change) and willing to remain weight stable throughout study * No change in blood pressure medications or other medications (prescription or dosing) in the prior 3 months and willing to maintain current medication regimen * Free from clinical disease with the exception of hypertension Exclusion Criteria: * Younger than age 50 years * Early menopause (menopause before age 45 years) * Having had a hysterectomy * History of uncontrolled hypertension (systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>120 mmHg) * Current smoker * Alcohol dependence or abuse * Abnormal blood pressure response to exercise (drop in systolic blood pressure below resting levels or systolic blood pressure \>260 mmHg or diastolic blood pressure \>115 mmHg) * Regular vigorous aerobic/endurance exercise (\>4 bouts/week, \>30 min/bout at a workload \>6 METS)
Conditions Cirrhosis, Hypersplenism, Hypertension, ...
Phase NA
Enrollment 15
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study aimed to evaluate the effectiveness and safety of vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection, and to assess its impact on postoperative digestive complications and quality of life.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Procedure: Vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection — The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.

Primary Outcomes

  • Incidence of Postoperative Diarrhea (3 months)
  • Incidence of Delayed Gastric Emptying (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-25
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northern Jiangsu People's Hospital
Principal Investigators:
  • Dou-Sheng Bai, MD (STUDY_CHAIR) - Clinical Medical College, Yangzhou University
  • Guo-Qing Jiang, MD (PRINCIPAL_INVESTIGATOR) - Clinical Medical College, Yangzhou University
Contact Information
Study Contact:
Guo-Qing Jiang, MD
+86-514-87373272
jgqing2003@hotmail.com
Dou-sheng Bai, MD
86-514-87373275
bdsno1@hotmail.com
Guo-Qing Jiang, MS
86-514-87373372
jgqing2003@hotmail.com
Clinical Medical College of Yangzhou University
Interventions
  • Procedure: Vagus nerve-guided laparoscopic splenectomy and azygoportal disconnection — The vagus nerve-guided procedure was performed in the following order: (1) find the left crural diaphragm; (2) via the surface of the left crural diaphragm, blunt dissect the left lateral surface of the distal esophagus using Bipolar Forceps, and find posterior vagal trunk; (3) along posterior vagal trunk towards left lateral esoph-agogastric junction, find and protect gastric and celiac branches; (4) enter the lesser omental sac from the right crural diaphragm using Bipolar Forceps; (5) transect the left gastric artery and vein together using a linear vascular stapler; (6) blunt dissect the anterior surface of the distal esophagus using Bipolar Forceps, and find anterior vagal trunk; (7) along anterior vagal trunk towards right lateral esoph-agogastric junction, find and protect gastric and hepatic branches; and (8) blunt dissect the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved.
Study Locations (2 sites)
Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu 225001 China
Clinical Medical College, Yangzhou University, Yangzhou, Jiangsu 225001 China
Eligibility Criteria
Inclusion Criteria: 1. A clinical, radiological or histologic diagnosis of cirrhosis of any etiology 2. Splenomegaly with secondary hypersplenism 3. Bleeding portal hypertension 4. No evidence of portal vein system thrombosis by ultrasound evaluation and angio-CT 5. Informed consent to participate in the study Exclusion Criteria: 1. Delayed gastric emptying 2. Diarrhea 3. Hepatocellular carcinoma or any other malignancy, 4. Hypercoagulable state other than the liver disease related 5. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs. 6. Child - Pugh C 7. Recent peptic ulcer disease 8. History of Hemorrhagic stroke 9. Pregnancy. 10. Uncontrolled Hypertension 11. Human immunodeficiency virus (HIV) infection

OCT in Rare Chorioretinal Diseases

NCT02141308
Recruiting
Conditions Retinal Artery Occlusions, Polypoidal Ch...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels. The purpose of measuring blood flow in the retina and choroid is to 1.) determine if rare diseases in these structures causes a change in blood flow compared to healthy eyes and 2.) find out if areas of changed blood flow line up with areas of damage that appear on conventional testing.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Total Retinal and Choroidal Blood Flow (One year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2014-05
Completion: 2026-12
Eligibility
Age: 7 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oregon Health and Science University
Principal Investigators:
  • Thomas Hwang, MD (PRINCIPAL_INVESTIGATOR) - Oregon Health & Science Univeristy
Contact Information
Study Contact:
Kevin Lathrop
503-494-8024
lathropk@ohsu.edu
Denny Romfh, OD
503-494-4351
romfhd@ohsu.edu
Kevin Lathrop
503-494-8024
lathropk@ohsu.edu
Casey Eye Institute, Oregon Health & Science University
Interventions
N/A
Study Locations (1 sites)
Casey Eye Institute, Oregon Health & Science University, Portland, Oregon 97239-3098 United States
Eligibility Criteria
Subject-Level Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to give informed consent. 2. Inability to complete study tests within a 30 day period 3. Significant renal disease, defined as a history of chornic renal failure requiring dialysis or kidney transplant. 4. A condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control). 5. Blood pressure \> 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible. 6. Women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 12 months due to unknown safety of fluorescein angiography. Study-Eye Criteria: Inclusion a. Diagnosis of retinal or choroidal disease Exclusion 1. Inability to maintain stable fixation for OCT imaging. 2. An ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (i.e. cataract) 3. Substantial cataract that, in the opinion of the investigator, is likely to decrease visual acuity by 3 lines or more (i.e. cataract would be reducing acuity to 20/40 or worse if the eye was otherwise normal). 4. Media opacity or otherwise that would prevent either fixation or ability to obtain adequate images as determined by the examiner.
Conditions Preeclampsia, Gestational Hypertension, ...
Phase NA
Enrollment 132
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Antihypertensive treatment — Antihypertensive treatment to goal of less than 140/90 mmHg

Primary Outcomes

  • Mean number of days from randomization to delivery (From randomization to delivery, up to 14 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-14
Completion: 2027-06
Eligibility
Age: 14 Years – 49 Years
Sex: FEMALE
Volunteers: false
Enrollment: 132 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alabama at Birmingham
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Rachel Sinkey, MD (PRINCIPAL_INVESTIGATOR) - University of Alabama at Birmingham
Contact Information
Study Contact:
Rachel Sinkey, MD
205-934-5611
rsinkey@uabmc.edu
Alan Tita, MD
205-934-5611
atita@uabmc.edu
Rachel Sinkey
2059345611
rsinkey@uabmc.edu
University of Alabama at Birmingham
Interventions
  • Drug: Antihypertensive treatment — Antihypertensive treatment to goal of less than 140/90 mmHg
Study Locations (2 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35233 United States
Oschner, New Orleans, Louisiana 70115 United States
Eligibility Criteria
Inclusion Criteria: * Pregnant women * Gestational age: 23 weeks, 0 days to 35 weeks, 6 days * Hypertensive disorder of pregnancy including gestational hypertension or preeclampsia, the non-severe form at enrollment, which is called without severe features by the American College of Obstetricians and Gynecologists. * No evidence of the severe form of preeclampsia, termed severe features, as outlined in maternal exclusions * No indication for delivery at the time of enrollment. * Planned expectant management at time of enrollment * Singleton or dichorionic twin gestation, defined at and beyond 14 weeks gestation. (A pregnancy complicated by a vanishing twin in the first trimester defined as less than 14 weeks gestation will be eligible.) * Intact membranes Exclusion Criteria: * Preeclampsia with severe features, defined per ACOG as: * Systolic blood pressure of 160 mm Hg or more, or diastolic blood pressure of 110 mm Hg or more on two occasions at least 4 hours apart (unless antihypertensive therapy is initiated before this time) * Thrombocytopenia defined as: lower than 100 x 10e9 platelets/L * Impaired liver function that is not accounted for by alternative diagnoses and as indicated by abnormally elevated blood concentrations of liver enzymes (to more than twice the upper limit normal concentrations), or by severe persistent right upper quadrant or epigastric pain unresponsive to medications * Renal insufficiency (serum creatinine concentration more than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease) * Pulmonary edema * New-onset headache unresponsive to medication and not accounted for by alternative diagnoses * Visual disturbances * Underlying renal dysfunction defined as, presenting the following parameters prior to 20 weeks gestation: baseline creatinine, equal to or higher than, 1.2 mg/dL Or proteinuria: defined as presenting protein in urine, equal to or higher than, 300 mg/24 hours or protein/creatinine ratio, equal to or higher than, 0.3 or Urine dipstick reading of greater than or equal to 2 at baseline and in the absence of a urinary tract infection * Stage 2 chronic hypertension * Contraindications to labetalol and nifedipine XL according to the FDA package insert * Patient unable to or unwilling to adhere to management recommendations * Fetal Reasons for Study Ineligibility: * Fetal growth restriction (lower than 10th percentile) at enrollment, based on an ultrasound within 3 weeks prior to enrollment * Oligohydramnios defined by amniotic fluid deepest vertical pocket \<2 cm based on an ultrasound within the 48 hours prior to enrollment * Known major structural or chromosomal abnormality

COMPERA / COMPERA-KIDS

NCT01347216
Recruiting
Conditions Pulmonary Arterial Hypertension (PAH), P...
Phase Not Applicable
Enrollment 14000
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH/PAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH/PH treatment in routine clinical care, the ongoing COMPERA registry prospectively documents consecutive patients with newly initiated treatment of PAH/PAH since May 2007. The internet-based registry fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in \>50% of participating centers). It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of other centers and the recommendations from guidelines. It is expected that the register contributes to optimization of specific drug therapy for PAH and PH. Since July 2013, also children of any age can be documented (COMPERA-KIDS).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of patients on monotherapy vs combination therapies at baseline and during follow-up (drug utilisation patterns) (Up to 10 years after inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2007-07-01
Completion: 2026-12-31
Eligibility
Age: 1 Week and older
Sex: ALL
Volunteers: false
Enrollment: 14000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Technische Universität Dresden
Collaborators: GWT-TUD GmbH
Principal Investigators:
  • Marius M Hoeper, MD, PhD (PRINCIPAL_INVESTIGATOR) - Department of Pulmonology, Medical School Hannover, Germany
  • Ardeschir H. Ghofrani, MD, PhD (STUDY_DIRECTOR) - Lung Centre, Giessen, Germany
  • Marion Delcroix, MD, PhD (STUDY_DIRECTOR) - Dept of Pneumology, University Leuven, Belgium
Contact Information
Study Contact:
David Pittrow, MD, PhD
+498152
david.pittrow@mailbox.tu-dresden.de
Marius M. Hoeper, MD, PhD
+49511532
Hoeper.Marius@mh-hannover.de
Marion Delcroix, MD, PhD
Dept. of Pneumology, University
Interventions
N/A
Study Locations (7 sites)
Dept. of Pneumology, University, Leuven, Belgium
DRK-Klinikum Köpenick, Berlin, Germany
Lung Centre, University of Giessen, Giessen, Germany
Department of Pulmology; Hannover Medical School, Hanover, Germany
German Heart Centre, Munich, Germany
Department of Cardiovascular and Respiratory Sciences, University La Sapienza, Rome, Italy
Dept. for Rheumatology, University Hospital, Zurich, Switzerland
Eligibility Criteria
Inclusion Criteria: * All age groups (amendment dated 1 June 2013) * Written informed consent * Pulmonary hypertension (PH) of either * PAH: idiopathic form (IPAH) or * PAH associated with connective tissue diseases (PAH-CTD), with congenital heart defects (PAH-CHD), with HIV infection (PAH-HIV), or the portopulmonary form * Chronic thromboembolic PH (CTEPH) * PH in left heart diseases (with isolated diastolic dysfunction; with systolic dysfunction, other) * PH in pulmonary disease (chronic obstructive pulmonary disease; interstitial fibrosis, etc.) * "Relative PH" in CHD after cavopulmonary anastomosis or Fontan-type surgery, even without the classical pulmonary pressure criteria of PH. * Newly initiated (i.e. a maximum of 3 months before documentation for the first time) therapy with endothelin receptor antagonists (ERA), phoshodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (sGC) stimulators or prostacyclins in mono- or combination therapy. Exceptions: PAH-CHD patients can be included on maintenance or newly initiated PAH therapy (3-month rule dose not apply). PAH-CHD patients with severe pulmonary vascular disease (e.g. Eisenmenger physiology) irrespective of treatment with any PAH drugs are eligible for inclusion, too. Exclusion Criteria: * Patients on maintenance therapy, i.e. previous treatment with any ERA/ PDE-5 inhibitor/prostacyclin/sGC stimulator drug longer than 3 months before documentation for the first time (exception: PAH-CHD patients).
Conditions Open Angle Glaucoma (OAG)
Phase NA
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to investigate the efficacy of cataract surgery in combination with Kahook Dual Blade Glide goniotomy (KDB) or iStent Inject W Trabecular Microbypass Stent (Istent) in eyes with Open-angle glaucoma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Goniotomy with KDB blade goniotomy — Goniotomy with KDB glide will be performed at the end of Cataract Surgery through the temporal cataract incision.
  • Device: Two iStent inject implanation — The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.

Primary Outcomes

  • Change in the number of intraocular pressure lowering medications compared to baseline (From enrollment to the end of treatment at 12 months)
  • Intraocular pressure measured by Goldmann applanation tonometry (GAT) (From enrollment to the end of treatment at 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-01
Completion: 2028-01-01
Eligibility
Age: 18 Weeks and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Bialystok
Contact Information
Study Contact:
Joanna Konopinska
+48600471666
joanna.konopinska@umb.edu.pl
Joanna Konopińska
600471666
joannakonopinska@o2.pl
Medical University of Bialystok
Joanna Konopińska, PhD
600471666
joannakonopinska@o2.pl
Ophthalmology Clinic Medical University of Bialystok
Interventions
  • Device: Goniotomy with KDB blade goniotomy — Goniotomy with KDB glide will be performed at the end of Cataract Surgery through the temporal cataract incision.
  • Device: Two iStent inject implanation — The two stents will be injected in Schlemms canal at the end of cataract surgery through the temporal cataract incision.
Study Locations (2 sites)
Medical University of Bialystok, Bialystok, Polska 15-866 Poland
Ophthalmology Clinic Medical University of Bialystok, Bialystok, 15-089 Poland
Eligibility Criteria
Inclusion Criteria: * Only one eye per participant * Clinically significant cataract * Glaucoma or intraocular hypertension treated with one to four medications and no need for filtering glaucoma surgery at the time of study enrollment. * Open chamber angle with Schaffer grading three to four in at least two quadrants Exclusion Criteria: * Previous glaucoma surgery, including cyclodestructive procedures. * Selective Laser Trabeculoplasty (SLT) within 90 days prior to planned surgery. * Exudative age-related macular degeneration, proliferative diabetic retinopathy, clinically significant corneal dystrophy, other eye disease that affect intraocular eye pressure or visual field. * Unable to participate and make written consent due to another medical condition.

Adaptive Optics Retinal Imaging

NCT05370287
Recruiting
Conditions Glaucoma, Primary Open Angle
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: oxygen inhalation — Subjects will breath 100% oxygen through a mask.
  • Device: Adaptive optics imaging — Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging

Primary Outcomes

  • Change in Retinal blood flow (RBF) with oxygen inhalation (RBF will be measured in all subjects twice during a single AO imaging session - once before and once during pure oxygen inhalation. Subjects will be imaged only once; there is no longitudinal component to this outcome measure.)
  • Retinal ganglion cell (RGC) density (RGC density will be calculated once at the AO imaging session in which RGCs are the target. For the reproducibility/longitudinal study portion, RGC density will be quantified three times over 1.5 years (visits separated by 6 months).)
  • RGC soma diameter (RGC diameter will be calculated once at the AO imaging session in which RGCs are the target. For the reproducibility/longitudinal portion of the study, RGC soma diameter will be quantified three times over 1.5 years (visits separated by 6 months).)
  • Retinal pigment epithelium (RPE) cell organelle motility (RPE organelle motility will be calculated once at the AO imaging session in which RPE cells are the target. For the reproducibility portion of the study, RPE organelle motility will be quantified three times over six weeks (visits separated by 2 weeks).)
  • Photoreceptor (PR) cell function (PR function will be calculated once at the AO imaging session in which photoreceptors are stimulated. For the reproducibility portion of the study, PR function will be quantified three times over six weeks (visits separated by 2 weeks).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2018-01-22
Completion: 2028-09-30
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Food and Drug Administration (FDA)
Collaborators: University of Maryland, Baltimore
Principal Investigators:
  • Daniel X Hammer, Ph.D. (PRINCIPAL_INVESTIGATOR) - Food and Drug Administration (FDA)
Contact Information
Study Contact:
Daniel X Hammer, Ph.D.
301-796-9320
daniel.hammer@fda.hhs.gov
Zhuolin Liu, Ph.D.
301-796-7914
zhuolin.liu@fda.hhs.gov
Daniel X Hammer, Ph.D.
301-796-9320
daniel.hammer@fda.hhs.gov
Food and Drug Administration
Interventions
  • Other: oxygen inhalation — Subjects will breath 100% oxygen through a mask.
  • Device: Adaptive optics imaging — Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
Study Locations (1 sites)
Food and Drug Administration, Silver Spring, Maryland 20993 United States
Eligibility Criteria
Inclusion Criteria: 1. Are 21 years of age or older. 2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam). 3. Have the ability to understand and sign an informed consent. 4. Have been diagnosed with POAG (cohort 2). Exclusion Criteria: 1. Are under 21 years of age. 2. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity). 3. Have visual correction outside of the range +4 diopters (D) to -8 D. 4. Have a history of adverse reaction to mydriatic drops. 5. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG). 6. Do not meet the criteria for POAG as defined by the American Academy of Ophthalmology Practice Patterns (cohort 2) 7. Have any health conditions that would contraindicate oxygen supplementation, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, or any other obstructive or restrictive lung disease (RBF experiment participants only). 8. Have a dependency on oxygen support or a baseline oxygen saturation \<95% (RBF experiment participants only). 9. Have tested positive for COVID-19 at initial enrollment or have acute or chronic photophobia as a result of contraction. 10. Are working under the direct supervision of Dr. Hammer.

BPA vs. PEA in CTEPH

NCT05110066
Recruiting
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase NA
Enrollment 139
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially life-threatening progressive disease that evolves from unresolved pulmonary embolism. Gold standard treatment for CTEPH is pulmonary endarterectomy (PEA) performed by skilled cardio-thoracic surgeons. Some patients may not be surgical candidates due to co-morbidities or because the vascular lesions are too distal making them technically inoperable. In these patients, balloon pulmonary angioplasty (BPA) has emerged as an effective treatment. In a subgroup of patients, the distribution of vascular lesions makes it possible to perform either BPA or PEA. There has never been a head-to head comparison of BPA with PEA. The aim of this study is therefore, to evaluate if BPA is non-inferior to PEA in patients with (CTEPH) who are eligible for both treatments.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Procedure: Pulmonary endarterectomy — Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
  • Procedure: Balloon pulmonary angioplasty — Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.

Primary Outcomes

  • Change in pulmonary vascular resistance (4 months and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2028-04-01
Eligibility
Age: 18 Years – 79 Years
Sex: ALL
Volunteers: false
Enrollment: 139 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Aarhus
Collaborators: Kerckhoff Klinik, Medical University of Vienna, Papworth Hospital NHS Foundation Trust, St. Antonius Hospital, Utrecht University, KU Leuven, Amsterdam UMC, location VUmc
Principal Investigators:
  • Irene Lang, MD,Prof (STUDY_CHAIR) - Medical University of Vienna
  • Harm Jan Bogaard, MD, Prof. (STUDY_CHAIR) - Amsterdam University Medical Center
  • Marion Delcroix, MD, Prof. (STUDY_CHAIR) - KU Leuven
Contact Information
Study Contact:
Asger Andersen, MD, ass.prof.
40138052
asger.andersen@clin.au.dk
Kristina Laut Matzen, RN,PhD
+4521673903
krlaut@clin.au.dk
Asger Andersen, PhD
Aarhus University Hospital
Interventions
  • Procedure: Pulmonary endarterectomy — Surgical pulmonary endarterectomy is done by a thoracic surgical procedure by removing chronic thrombotic material by intimal dissection with patient on cardiopulmonary bypass.
  • Procedure: Balloon pulmonary angioplasty — Percutaneous balloon pulmonary angioplasty is performed using standard percutaneous technique to break the fibrotic clots in the pulmonary arteries using percutaneous transluminal angioplasty balloons.
Study Locations (2 sites)
Aarhus University Hospital, Aarhus, Denmark
Royal Ppworth, Cambridge, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Diagnosed with chronic thromboembolic pulmonary hypertension according to current European society of cardiology/European Respiratory Society guidelines and eligible for both pulmonary endarterectomy and ballon pulmonary angioplasty by decision at the local multidisciplinary team conference and central adjudication committee * Written informed consent from the patient * Patient age \>17 and \<80 years * Able to understand and follow instructions and to participate in the entire study period Exclusion Criteria: * Life expectancy \<12 months * Co morbidities evaluated at the multidisciplinary team conference, that contributes significantly to the patients pulmonary hypertension * Not possible to perform balloon pulmonary angioplasty or pulmonary endarterectomy within 4 months after randomization. * Evaluated at multidisciplinary team conference that changes in pulmonary artery hypertension targeted therapy between baseline and 4 months follow-up is inevitable\* * Known pregnancy or positive urine Human chorionic gonadotropin screening test in fertile women * Previous balloon pulmonary angioplasty or pulmonary endarterectomy
Conditions Stasis Dermatitis
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

This study tests two types of lasers (ND YAG 1064 short and ultra-short pulses) to treat hyperchromic skin lesions secondary to venous hypertension (stasis dermatitis)

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: short-pulse ND: YAG 1064 laser — Nd: YAG 1064 nm short pulse laser (5 nanoseconds), 4 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Smart, a Q-Switch Laser produced by Medical San (Lajeado, RS, Brazil).
  • Procedure: ultra-short-pulse ND: YAG 1064 laser — Nd: YAG1064 nm ultra-short pulse laser (400 picoseconds), 2 to 10 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for 6 visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Premium, a picolaser produced by Medical San (Lajeado, RS, Brazil).
  • Drug: cold cream — The control vehicle is a cold cream, supplied by HERVA'S manipulation pharmacy. The composition of cold cream will be beeswax, acetyl palmitate, BHA, cetearyl alcohol, propylparaben, and water. This topical agent will be applied to patients daily throughout the treatment period. It is scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days.

Primary Outcomes

  • Colorimetry (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-20
Completion: 2026-12-01
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Science Valley Research Institute
Principal Investigators:
  • Eduardo Ramacciotti, MD, Ph.D, livre docente (STUDY_CHAIR) - Science Valley Research Institute
Contact Information
Study Contact:
Valéria Aguiar, MD
+5511950212099
val.aguiarvasc@gmail.com
Valeria Aguiar, MD
+55 11 95021-2099
val.aguiarvasc@gmail.com
Clinica Ramacciotti
Interventions
  • Procedure: short-pulse ND: YAG 1064 laser — Nd: YAG 1064 nm short pulse laser (5 nanoseconds), 4 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Smart, a Q-Switch Laser produced by Medical San (Lajeado, RS, Brazil).
  • Procedure: ultra-short-pulse ND: YAG 1064 laser — Nd: YAG1064 nm ultra-short pulse laser (400 picoseconds), 2 to 10 mm spot size, from 100 to 1000 mJ total energy, treatment scheduled for 6 visits with pre-defined dates, with intervals of 28 to 35 days. The device will be Omer Premium, a picolaser produced by Medical San (Lajeado, RS, Brazil).
  • Drug: cold cream — The control vehicle is a cold cream, supplied by HERVA'S manipulation pharmacy. The composition of cold cream will be beeswax, acetyl palmitate, BHA, cetearyl alcohol, propylparaben, and water. This topical agent will be applied to patients daily throughout the treatment period. It is scheduled for six visits with pre-defined dates, with intervals of 28 to 35 days.
Study Locations (1 sites)
Clinica Ramacciotti, Santo André, São Paulo 09090401 Brazil
Eligibility Criteria
Inclusion Criteria: 1. Women or men aged 18 to 89 years with stasis dermatitis secondary to venous hypertension 2. Agreement with the terms of the survey and signing of the informed consent form 3. Availability to make the necessary appointments for treatment and follow-up 4. Provide consent to avoid pregnancy during treatment 5. Have primary venous hypertension already treated (treatment of varicose veins of the lower limbs) by any of the available techniques Exclusion Criteria: 1. Men and women with CEAP 2 to 6, low mobility, no stasis dermatitis. 2. Peripheral arterial disease. 3. History of known allergy to the drugs used in this study 4. Presence of other types of dermatitis in the lower extremities, such as allergic stasis eczema. 5. Presence of comorbidities (such as diabetes mellitus, heart failure, respiratory failure, hypertension, hypothyroidism, or hyperthyroidism), pregnancy, breastfeeding, pulmonary hypertension, deep vein thrombosis (DVT), family history of DVT, known hypercoagulable states or thrombophilia, asthma, and migraine. 6. Anyone who does not agree with any of the search terms. \-
Conditions Ovarian Cancer, Pancreas Cancer, Urothel...
Phase PHASE1
Enrollment 100
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-16
Study Details Design, interventions, and primary outcomes

About This Study

Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical starting dose. Dose escalation in solid tumors (Part A1) will be followed by dose finding in multiple myeloma (Part A2). Part B consists of dose expansion in solid tumors (Part B1) and multiple myeloma (Part B2) using the recommended dose for expansion from Part A

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: QXL138AM Injection every 2 weeks by IV Infusion — masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a

Primary Outcomes

  • Incidence of Adverse Events (Throughout study - anticipated 3.5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-08-28
Completion: 2028-05-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nammi Therapeutics Inc
Principal Investigators:
  • Dennis Kim, MD (STUDY_DIRECTOR) - Nammi Therapeutics Inc
Contact Information
Study Contact:
David Stover, PhD
818-926-3428
David.Stover@nammirx.com
Anthony El-Khoueiry, MD
323-865-3962
elkhouei@med.usc.edu
University of Southern California
Kamya Sankar, MD
248-802-2041
kamya.sankar@cshs.org
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer
Interventions
  • Biological: QXL138AM Injection every 2 weeks by IV Infusion — masked immuno-cytokine comprised of an anti-CD138 IgG1 antibody fused to human interferon alpha 2a
Study Locations (10 sites)
University of Southern California, Los Angeles, California 90033 United States
Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles, California 90048 United States
Cedars-Sanai Medical Center, Los Angeles, California 90048 United States
Hoag Memorial Hospital Presbyterian, Newport, California 92663 United States
Sarah Cannon Research Institute - Denver DDU, Denver, Colorado 80218 United States
Emory University - Winship Cancer Institute, Atlanta, Georgia 30322 United States
New York Cancer & Blood Specialists, New York, New York 11967 United States
University of Rochester - Wilmot Cancer Institute, Rochester, New York 14642 United States
START San Antonio, San Antonio, Texas 78229 United States
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Eligibility Criteria
Inclusion Criteria: 1. Participants with Solid Tumors * Histopathologically confirmed diagnosis of an advanced, unresectable, or metastatic solid tumor (ovarian, pancreatic, urothelial, renal, hepatocellular, gastrointestinal (GI), lung, prostate, and breast cancer). * Have progressed despite standard therapies, or for whom conventional therapy is not effective or tolerable, as judged by the Investigator. Patients must have no available therapeutic options known to confer clinical benefit for their tumor type. 2. Participants with Multiple Myeloma * Have progressed despite standard therapies, or for whom conventional therapy is not effective or tolerable, as judged by the Investigator. * Patients must have failed at least 3 prior therapies for myeloma and should have had prior exposure to a proteosome inhibitor, an IMiD, and an anti-CD38-directed therapy. 2\. Male or female participants ≥18 years of age at the time of informed consent 3. An Eastern Cooperative Oncology Group (ECOG) performance status scale of 0, 1, or 2 at Screening 4. Must have at least 1 measurable lesion by RECIST version 1.1 (solid tumors only), or evaluable disease by IMWG Uniform Response Criteria (multiple myeloma only) 5. Adequate organ function and bone marrow reserve 6. Adequate cardiac function as estimated by left ventricular ejection fraction 7. Female participants of child-bearing potential must: * Have a negative serum pregnancy test at screening and a negative pregnancy test at Week 1 Day 1 prior to first dose of QXL138AM, AND * Agree to use at least 1 highly effective method of contraception for the duration of study participation, and for 120 days after last dose of QXL138AM. 8\. Male participants of child-bearing potential must: * Agree to use at least 1 highly effective method of contraception for the duration of study participation, and for 120 days after last dose of QXL138AM, AND * Refrain from sperm donation prior to the first dose of investigational product through 120 days following the last dose of QXL138AM. Exclusion Criteria: 1. New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, a history of risk factors for Torsades de Pointes (TdP), including heart failure, hypokalemia, and family history of long QTc syndrome, or evidence of ischemia on ECG. Symptomatic ischemic heart disease or unstable angina pectoris; or history of cardiac angioplasty, cardiac stenting, or coronary artery bypass graft. A clinically significant baseline prolongation of QT/QTcF interval at screening. 2. The use of concomitant medications that may significantly prolong the QT/QTc interval. 3. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy. 4. Known hypersensitivity to the investigational product or components (anti-CD138 IgG1 antibody, Interferon A2a and/or the formulation excipients: histidine, sucrose, arginine, polysorbate 80). 5. Female participant is lactating. 6. Any other clinically significant comorbidities. 7. Received prior anticancer therapy within 28 days or 5x the half-life (whichever is shorter) prior to the first dose of investigational product. 8. Participants who received wide-field radiation therapy within 4 weeks prior to first dose of investigational product, (2 weeks for limited field radiation therapy) 9. Major surgery within 30 days before first dose of investigational product 10. Chronic use of systemic corticosteroids of more than 20 mg/day of prednisone or equivalent. 11. Active, clinically significant liver disease such as Hepatitis B or C, autoimmune hepatitis, or cirrhosis (Child Hugh Stage B or C). 12. Current or history of mood disorder such as major depression per DSM-5 within past two years not controlled with current therapy. 13. Active autoimmune disorders not controlled with current therapy. 14. Active endocrine disorders including hypothyroidism, hyperthyroidism, hypoglycemia, hyperglycemia, and diabetes mellitus not controlled with current therapy.